Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 4, pp 550–553 | Cite as

Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age

  • I. B. Antonov
  • K. L. Kozlov
  • E. M. Pal’tseva
  • O. V. Polyakova
  • N. S. Lin’kova
Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
  • 32 Downloads

We studied the expression of MMP-2, MMP-9, and inhibitor TIMP-1 in myocardial autopsy samples from subjects of different age and in cardiomyocyte cultures in the norm and in dilated cardiomyopathy. In autopsy samples of normal myocardium and in cardiomyocyte cultures, expression of molecules involved in extracellular matrix remodeling did not change during aging. In dilation cardiomyopathy, expression of MMP-2, MMP-9, and TIMP-1 and their ratios in autopsy material and in cultures was elevated by 1.5-9 times. Remodeling of extracellular matrix plays an important role in the pathogenesis of dilated cardiomyopathy. MMP-2, MMP-9, and their inhibitor TIMP-1 and the MMP/TIMP ratios can be regarded as promising predictors of dilated cardiomyopathy and used for evaluation of the effectiveness of treatment of this conditions in patients of different ages.

Key Words

MMP-2 MMP-9 TIMP-1 dilated cardiomyopathy aging 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gurevich MA, Arkhipova LV. Principles of therapy of chronic heart failure in patients with dilated cardiomyopathy. Bol. Serdtsa Sosudov. 2011;6(1):37-40. Russian.Google Scholar
  2. 2.
    Tereshchenko SN, Alaeva EN, Narusov OYu, Kochetov AG, Skvortsov AA. Diagnosis and treatment of dilated cardiomyopathy in common clinical practice (Primary data of the Russian register of dilated cardiomyopathy). Kardiol. Vestn. 2014;9(2):54-61. Russian.Google Scholar
  3. 3.
    Bornstein P, Sage EN. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell. Biol. 2002;14(5):608-616.CrossRefPubMedGoogle Scholar
  4. 4.
    Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix Metalloproteinase Inhibition after Myocardial Infarction: a new approach to prevent heart failure? Circ. Res. 2001;89(3):201-210.CrossRefPubMedGoogle Scholar
  5. 5.
    Ju C, Ye M, Li F. Plasma brain natriuretic peptide, endothelin-1, and matrix metalloproteinase 9 expression and significance in Type 2 diabetes mellitus patients with ischemic heart disease. Med. Sci. Monit. 2015;21:2094-2099.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jungbauer CG, Riedlinger J, Block D, Stadler S, Birner C, Buesing M, König W, Riegger G, Maier L, Luchner A. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark. Med. 2014;8(6):777-789.CrossRefPubMedGoogle Scholar
  7. 7.
    Li X, Lu Y, Sun Y, Zhang Q. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. Int. J. Clin. Exp. Pathol. 2015;8(6):7247-7253.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, Cambien F, Tiret L, Münzel T, Blankenberg S. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the atherogene study. Eur. Heart J. 2006;27(2):150-156.CrossRefPubMedGoogle Scholar
  9. 9.
    Morine KJ, Paruchuri V, Qiao X, Mohammad N, Mcgraw A, Yunis A, Jaffe I, Kapur NK. Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis. Biomarkers. 2016;21(1):91-97.CrossRefPubMedGoogle Scholar
  10. 10.
    Nepomnyashchikh LM, Lushnikova EL, Bakarev MA, Nikityuk DB, Yuzhik EI, Mzhelskaya MM, Nepomnyashchikh RD, Klinnikova MG, Karpova AA. Immunohistochemical analysis of MMP-2 expression in the myocardium during the postinfarction period. Bull. Exp. Biol. Med. 2015;159(4):505-510.CrossRefPubMedGoogle Scholar
  11. 11.
    Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin. Res. Cardiol. 2006;95(5):261-269.CrossRefPubMedGoogle Scholar
  12. 12.
    Rita Balistreri C, Allegra A, Crapanzano F, Pisano C, Ruvolo G. Matrix Metalloproteinases (MMPs), their genetic variants and miRNA in mitral valve diseases: potential biomarker tools and targets for personalized treatments. J. Heart Valve Dis. 2016;25(4):463-474.PubMedGoogle Scholar
  13. 13.
    Rutschow S, Leschka S, Westermann D, Puhl K, Weitz A, Ladyszenskij L, Jaeger S, Zeichhardt H, Noutsias M, Schultheiss HP, Tschope C, Pauschinger M. Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis-ongoing inflammation and an imbalance of the matrix degrading system. Eur. J. Pharmacol. 2010;630(1-3):145-151.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • I. B. Antonov
    • 1
  • K. L. Kozlov
    • 1
  • E. M. Pal’tseva
    • 2
  • O. V. Polyakova
    • 3
  • N. S. Lin’kova
    • 1
    • 4
  1. 1.St. Petersburg Institute of Bioregulation and GerontologySt. PetersburgRussia
  2. 2.B. V. Petrovsky Russian Surgery Research CenterMoscowRussia
  3. 3.D. O. Ott Research Institute of Obstetrics, Gynecology, and ReproductologySt. PetersburgRussia
  4. 4.Peter the Great St. Petersburg State Polytechnic UniversitySt. PetersburgRussia

Personalised recommendations